Genentech/Roche proposes the use of FHTR2163 (Genentech/Roche), a new antibody delivered by intravitreal injection that inhibits HTRA1, a serine protease gene HTRA1 as a major risk factor for wet AMD [Phase 2/NCT03972709 (Dewan et al., 2006)]. Here, HTRA1 is linked to wet macular degeneration.